These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 8320039

  • 1. Cyclic V3-loop-related HIV-1 conjugate vaccines. Synthesis, conformation and immunological properties.
    Tolman RL, Bednarek MA, Johnson BA, Leanza WJ, Marburg S, Underwood DJ, Emini EA, Conley AJ.
    Int J Pept Protein Res; 1993 May; 41(5):455-66. PubMed ID: 8320039
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens.
    Conley AJ, Conard P, Bondy S, Dolan CA, Hannah J, Leanza WJ, Marburg S, Rivetna M, Rusiecki VK, Sugg EE.
    Vaccine; 1994 Apr; 12(5):445-51. PubMed ID: 8023553
    [Abstract] [Full Text] [Related]

  • 3. Identification of HIV vaccine candidate peptides by screening random phage epitope libraries.
    Keller PM, Arnold BA, Shaw AR, Tolman RL, Van Middlesworth F, Bondy S, Rusiecki VK, Koenig S, Zolla-Pazner S, Conard P.
    Virology; 1993 Apr; 193(2):709-16. PubMed ID: 7681612
    [Abstract] [Full Text] [Related]

  • 4. Induction of high levels of epitope-specific antibodies by epitope/peptide candidate vaccines against human immunodeficiency virus type-1 (HIV-1).
    Yu T, Bai Y, Dierich MP, Chen YH.
    Microbiol Immunol; 2000 Apr; 44(2):105-10. PubMed ID: 10803497
    [Abstract] [Full Text] [Related]

  • 5. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY, Luo L, Wainberg MA, Li Y.
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [Abstract] [Full Text] [Related]

  • 6. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM, McKeating JA, de Souza JB, Roitt IM, Delves PJ, Lund T.
    Virology; 1998 Nov 10; 251(1):59-70. PubMed ID: 9813203
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R, Meyer D.
    Vaccine; 2005 Mar 18; 23(17-18):2164-7. PubMed ID: 15755588
    [Abstract] [Full Text] [Related]

  • 8. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.
    Liao HX, Cianciolo GJ, Staats HF, Scearce RM, Lapple DM, Stauffer SH, Thomasch JR, Pizzo SV, Montefiori DC, Hagen M, Eldridge J, Haynes BF.
    Vaccine; 2002 May 22; 20(17-18):2396-403. PubMed ID: 12009296
    [Abstract] [Full Text] [Related]

  • 9. Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice.
    Boudet F, Keller H, Kieny MP, Thèze J.
    Mol Immunol; 1995 May 22; 32(7):449-57. PubMed ID: 7783749
    [Abstract] [Full Text] [Related]

  • 10. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD, Pendleton CD, Dunlop N, Minassian A, Nara PL, Berzofsky JA.
    J Immunol; 1993 Jun 15; 150(12):5647-65. PubMed ID: 8515081
    [Abstract] [Full Text] [Related]

  • 11. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.
    Letvin NL, Robinson S, Rohne D, Axthelm MK, Fanton JW, Bilska M, Palker TJ, Liao HX, Haynes BF, Montefiori DC.
    J Virol; 2001 May 15; 75(9):4165-75. PubMed ID: 11287566
    [Abstract] [Full Text] [Related]

  • 12. Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1).
    Laisney IL, Strosberg AD.
    Immunol Lett; 1999 Apr 15; 67(3):185-92. PubMed ID: 10369125
    [Abstract] [Full Text] [Related]

  • 13. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M, Qiao ZS, Montefiori DC, Haynes BF, Reinherz EL, Liao HX.
    AIDS Res Hum Retroviruses; 2005 Jan 15; 21(1):58-67. PubMed ID: 15665645
    [Abstract] [Full Text] [Related]

  • 14. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC, Stuber G, Wagner R, Wolf H, Modrow S.
    J Pept Sci; 1995 Jan 15; 1(2):109-23. PubMed ID: 9222988
    [Abstract] [Full Text] [Related]

  • 15. Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp 120.
    Nehete PN, Casement KS, Arlinghaus RB, Sastry KJ.
    Cell Immunol; 1995 Feb 15; 160(2):217-23. PubMed ID: 7720083
    [Abstract] [Full Text] [Related]

  • 16. HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D.
    Mester B, Manor R, Mor A, Arshava B, Rosen O, Ding FX, Naider F, Anglister J.
    Biochemistry; 2009 Aug 25; 48(33):7867-77. PubMed ID: 19552398
    [Abstract] [Full Text] [Related]

  • 17. A structure-based approach to a synthetic vaccine for HIV-1.
    Cabezas E, Wang M, Parren PW, Stanfield RL, Satterthwait AC.
    Biochemistry; 2000 Nov 28; 39(47):14377-91. PubMed ID: 11087390
    [Abstract] [Full Text] [Related]

  • 18. Negatively charged glyconanoparticles modulate and stabilize the secondary structures of a gp120 V3 loop peptide: toward fully synthetic HIV vaccine candidates.
    Gianvincenzo PD, Calvo J, Perez S, Álvarez A, Bedoya LM, Alcamí J, Penadés S.
    Bioconjug Chem; 2015 Apr 15; 26(4):755-65. PubMed ID: 25734507
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Preliminary results of V3 loop peptide-primary neutralizing domain conjugate phase 1 vaccine trail.
    Rubinstein A, Goldstein H, Pettoello-Mantovani M, Cryz SJ.
    AIDS Res Hum Retroviruses; 1994 Apr 15; 10 Suppl 2():S149-53. PubMed ID: 7865291
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.